6 papers in the library · 93 citations · publishing 2023-2026
American Journal of Bioethics 2026 Katherine Cheung, Brian D. Earp, Kyle Patch et al.
We are grateful to those who commented on our Target Article on ethical exceptionalism around psychedelics (see Box 1 for a summary of our main points) and to Cohen and Marks (2025) for their compl...
AJOB empirical bioethics July 16, 2025 Katherine Cheung, Caleigh Propes, Marianna Graziosi et al. 4 citations
Classic psychedelics, such as psilocybin and LSD, evoke certain kinds of altered states of consciousness. Specific features of the experience, such as its allegedly ineffable nature, have been discussed as posing challenges to the informed consent process. A growing call for tailored informed consent documents (ICDs) in the psychedelic bioethics literature raises the question of how closely...
Journal of psychopharmacology (Oxford, England) May 26, 2025 Kyle Patch, William R. Smith 3 citations
Research on the therapeutic potential of psychedelics has surged, prompting a re-examination of the role of set and setting in psychedelic-assisted therapy. Yet, these concepts are vague and typically defined over inclusively. We believe that set and setting research should be methodologically reductionist, focusing on specific components rather than set and setting as such. To that end, we...
The American journal of bioethics : AJOB 2025 Katherine Cheung, Brian D. Earp, Kyle Patch et al. 30 citations
When used clinically, psychedelics may appear unusual or even unique when compared to more familiar or long-standing medical interventions, prompting some to suggest that the ethical issues raised may likewise be exceptional. If that is correct, then perhaps psychedelics should be treated differently from other medical substances: for example, by being subjected to different ethical or...
American Journal of Bioethics May 2, 2024 Edward Jacobs, Brian D. Earp, Paul S. Appelbaum et al. 29 citations
The first Hopkins-Oxford Psychedelic Ethics (HOPE) workshop convened to discuss ethical matters relating to psychedelics in August 2023 at the University of Oxford.The organizers (BDE, DBY, EJ) aim...
Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees June 27, 2023 Katherine Cheung, Kyle Patch, Brian D. Earp et al. 27 citations
Psychedelics such as psilocybin reliably produce significantly altered states of consciousness with a variety of subjectively experienced effects. These include certain changes to perception, cognition, and affect,1 which we refer to here as the acute subjective effects of psychedelics. In recent years, psychedelics such as psilocybin have also shown considerable promise as therapeutic agents...